BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AusBiotech Ltd. Announces New Board Appointment


5/29/2012 9:30:54 AM

May 29, 2012 -- AusBiotech today announced the appointment of Dr Mark Harvey to its Board, to join the leadership team of AusBiotech in its efforts to grow and attract capital to the biotechnology industry.

Chair of the AusBiotech Board, Dr Deborah Rathjen, said: “I’m pleased to announce the invited appointment to the AusBiotech Board of well-respected investment manager and venture capitalist, Dr Mark Harvey.”

“With capital widely-acknowledged as the ‘life-blood’ of Australia’s promising biotechnology sector, Mark’s expertise in the investment community and specific experience in the life sciences sector will make him a valuable addition to the Board.”

The AusBiotech constitution allows for both elected and appointed Board members, to ensure balanced representation, skills and experience, to enable effective leadership of the industry organisation.

“The appointment reflects AusBiotech’s focus on the attraction of capital to the sector and supports the work being undertaken at a policy level and in the AusBiotech global investment series, which provides a platform for Australian companies seeking partnering and investment,” said Dr Rathjen.

Dr Mark Harvey is a Partner with CM Capital Investments, one of Australia’s leading venture capital companies with over $250 million under management. Mark has over 20 years’ experience in medical research, technology transfer and commercialisation, and has played key roles in the formation, fund raising, and management of numerous life science companies. Mark is a member of the Board of Directors of Sunshine Heart, a NASDAQ and ASX-listed company developing a treatment for heat failure; Osprey Medical Inc, an ASX-listed medical device company commercialising a coronary catheter system; and Pathway Therapeutics Inc, a clinical-stage oncology company based in San Francisco.

“I am delighted to join the AusBiotech Board and contribute to the vital role that AusBiotech performs so diligently for our industry,” said Dr Harvey.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->